NEW YORK (GenomeWeb News) – Becton Dickinson has exclusive rights to negotiate an acquisition of TriPath Imaging, according to documents filed with the Securities and Exchange Commission yesterday.
As GenomeWeb News reported on Tuesday, Becton Dickinson offered buy all outstanding TriPath shares for $9.25 each, or about $350 million. The company currently holds a 6.5-percent stake in TriPath.
According to the filing, the exclusive agreement is in place until Aug. 25. If TriPath violates the agreement, it will pay Becton Dickinson $5 million in termination fees.